RQ Bio announces exec appointments

6 October 2026

UK privately-held biotech RQ Bio has announced the appointment of Gavin Koh as chief medical officer (CMO).

Dr Koh brings 20 years of pharmaceutical industry drug development and infectious diseases experience. Prior to joining RQ Bio, he held senior roles at UK pharma majors AstraZeneca (LSE: AZN) and GSK, (LSE: GSK) leading programs from discovery to registration and launch, including Evusheld during the COVID-19 pandemic.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biotechnology